Close Menu

Pfizer has acquired the worldwide rights to sell insulin and insulin analogs being developed by Indian biotech company Biocon, in an attempt to work its way into the generic biotech drug market, says the New York Times' Andrew Pollack in the Prescriptions blog. Pfizer will pay Biocon $200 million initially, and then another $150 million, while Biocon manufactures the insulin. Other pharma companies are also getting into the biologic market, Pollack says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.